{"schema_version":"secwatch.filing_event.v1","accession":"0001789769-26-000044","form_type":"8-K","ticker":"TIL","cik":"0001789769","company_name":"Instil Bio, Inc.","filed_at":"2026-05-15T12:30:17+00:00","discovered_at":"2026-05-15T12:35:00.324605+00:00","generated_at":"2026-05-15T12:36:01.209791+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Instil Bio reports Q1 2026 cash of $74.7M, GAAP net loss per share $0.62","bullets":["Cash, equivalents, restricted cash and marketable securities $74.7M as of March 31, 2026; expected to fund operations beyond 2027.","GAAP net loss per share $0.62; non-GAAP net loss per share $0.32 for Q1 2026.","R&D expenses $0.7M (down from $5.4M YoY); G&A expenses $5.3M (down from $9.1M).","Company actively evaluating potential acquisitions and in-licensing opportunities for novel therapeutic candidates."],"urls":{"canonical":"https://secwatch.observer/filing/0001789769-26-000044","json":"https://secwatch.observer/filing/0001789769-26-000044.json","markdown":"https://secwatch.observer/filing/0001789769-26-000044.md","text":"https://secwatch.observer/filing/0001789769-26-000044.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1789769/000178976926000044/0001789769-26-000044-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1789769/000178976926000044/til-20260515.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T12:36:01.209791+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"70e4b172a1b867249d79c90d2a9741513c7b78b1","claim":"Instil Bio, Inc. reported the quarter ended March 31, 2026 results: EPS Net loss per share, basic and diluted was $0.62 for the three months ended March 31, 2026.","evidence_excerpt":"Net loss per share, basic and diluted was $0.62 for the three months ended March 31, 2026, compared to $4.32 for the three months ended March 31, 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1789769/000178976926000044/0001789769-26-000044-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2026"},{"label":"EPS","value":"Net loss per share, basic and diluted was $0.62 for the three months ended March 31, 2026"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}